Kolkata, West Bengal -- (SBWIRE) -- 09/18/2013 -- Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on Applied Materials, Inc.(NASDAQ:AMAT), Merck & Co., Inc.(NYSE:MRK), Charles Schwab Corp (NYSE:SCHW).
Applied Materials, Inc.(NASDAQ:AMAT) shares dropped 0.28% to $15.90. The company on Sept. 9 announced that its Board of Directors has approved a quarterly cash dividend of $0.10 per share payable on the company`s common stock. The dividend is payable on December 12, 2013 to stockholders of record as of November 21, 2013.
Additionally, the company on August 16 said that its fiscal third-quarter net income fell 23% while revenue fell 16%. Both totals came up short of analyst expectations. The company said its income totaled 18 cents per share excluding special items. Analysts expected 19 cents per share on revenue of $2.06 billion. The company said it took $2 billion in orders, which was less than it received in the second quarter.
Looking forward, the company said it expects to earn between 16 and 20 cents per share in the fourth quarter. Revenue is expected to be about the same as the $1.98 billion it reported in the third quarter. Analysts were expecting income of 21 cents per share and $2.15 billion in revenue, according to FactSet.
Should Investors Buy AMAT After Yesterday’s Jump? Find Out Here
Merck & Co., Inc.(NYSE:MRK) shares fell 0.37% and closed at $48.01. The company on Sept. 17 announced that it has been named as one of the Working Mother 100 Best Companies for 2013. Honored on the list for the 26th year, Merck is among the 100 companies recognized for their commitment to progressive workplace programs, including female representation, compensation, child care, flexibility, time off and leave, family-friendly programs and company culture. Those chosen also demonstrated their commitment to supporting working moms to be healthy.
Additionally, the company on Sept. 11 announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer.
Moreover, the company on Sept. 9 announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck is seeking FDA approval of corifollitropin alfa for Controlled Ovarian Stimulation (COS) in women participating in assisted reproductive technology. If approved, corifollitropin alfa would be the first sustained follicular stimulant for use in a fertility treatment regimen.
How Should Investors Trade MRK After The Recent Volatility? Get Free Trend Analysis Here
Charles Schwab Corp (NYSE:SCHW) stock gained 2.54% to $22.64. The company on Sept. 16 said its daily trading volume declined in August from July, but was up from a year earlier. Schwab said its daily average client trades totaled 467,300 last month, up 24% from a year earlier, but down 6% from July. Total client assets reached $2.08 trillion in August, up 12% year to year, but down 2% from July. Net new assets were a negative $2.4 billion.
Additionally, On Sep 3, 2013, Zacks reaffirmed their Neutral recommendation on The Charles Schwab Corporation (SCHW). Though the company reported lower-than-expected second-quarter results, the initiatives to improve capital ratios and effective capital deployment activities are impressive.
Is SCHW A Good Buy After The Recent Price Movement? Find Out Here
Specialpennystockalert.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Specialpennystockalert.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by Specialpennystockalert.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Specialpennystockalert.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)